A detailed history of Dcf Advisers, LLC transactions in Amgen Inc stock. As of the latest transaction made, Dcf Advisers, LLC holds 8,500 shares of AMGN stock, worth $2.69 Million. This represents 1.44% of its overall portfolio holdings.

Number of Shares
8,500
Previous 10,300 17.48%
Holding current value
$2.69 Million
Previous $2.93 Million 9.32%
% of portfolio
1.44%
Previous 1.49%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$262.75 - $319.31 $472,950 - $574,758
-1,800 Reduced 17.48%
8,500 $2.66 Million
Q1 2024

May 15, 2024

BUY
$268.87 - $324.56 $887,271 - $1.07 Million
3,300 Added 47.14%
10,300 $2.93 Million
Q4 2023

Feb 13, 2024

SELL
$255.7 - $288.46 $357,980 - $403,844
-1,400 Reduced 16.67%
7,000 $2.02 Million
Q3 2023

Nov 13, 2023

SELL
$218.65 - $271.46 $1.85 Million - $2.3 Million
-8,475 Reduced 50.22%
8,400 $2.26 Million
Q2 2023

Aug 09, 2023

BUY
$214.27 - $253.37 $1.47 Million - $1.74 Million
6,875 Added 68.75%
16,875 $3.75 Million
Q1 2023

May 15, 2023

BUY
$225.79 - $275.2 $2.26 Million - $2.75 Million
10,000 New
10,000 $2.42 Million
Q1 2022

May 13, 2022

SELL
$219.27 - $242.57 $2.8 Million - $3.09 Million
-12,750 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$198.88 - $227.6 $298,320 - $341,400
1,500 Added 13.33%
12,750 $2.87 Million
Q3 2020

Nov 13, 2020

SELL
$234.65 - $260.95 $117,325 - $130,475
-500 Reduced 4.26%
11,250 $2.86 Million
Q2 2020

Aug 13, 2020

SELL
$197.81 - $242.74 $296,715 - $364,110
-1,500 Reduced 11.32%
11,750 $2.77 Million
Q1 2020

May 12, 2020

BUY
$182.24 - $241.7 $136,680 - $181,275
750 Added 6.0%
13,250 $2.69 Million
Q4 2019

Feb 12, 2020

BUY
$189.21 - $243.2 $2.37 Million - $3.04 Million
12,500 New
12,500 $3.01 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $169B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Dcf Advisers, LLC Portfolio

Follow Dcf Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dcf Advisers, LLC with notifications on news.